Dr Clarke criticised the methods and the external validity of the vascular dementia project conducted in the framework of the double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. [1] [2] [3] He argued that the trial stopped prematurely, that the incidence of dementia in the placebo group was low, and that a P-value of 0.05 should not be taken as statistically significant. It is correct that the original sample size calculations projected a total of 3000 patients to be followed for 5 years. 1 However, after a median follow-up of 2 years, there was no option other than to stop the trial because of the 42% reduction in the occurrence of stroke, 4 the primary endpoint. 5 Furthermore, in the intention-to-treat analysis, the incidence of dementia in the placebo group was only half the projected rate (7.7 vs 16.0 cases per 1000 patient-years). However, in contrast to Dr Clarke's interpretation, both the short follow-up and the low risk of dementia worked against the demonstration of significant protection against cognitive impairment. Had 3000 patients been followed for 5 years at the observed levels of risk and benefit, 3 the P-value would have been less than 0.01 instead of 0.05. Furthermore, the P-value for the reduction of dementia in the per-protocol analysis was 0.03. 3 These P-values, regardless of whether they were projected 1 or observed, 3 are compatible with statistical significance for a twosided hypothesis tested on a single occasion. Thus, the observation that significant benefit could be demonstrated in spite of only 2 years of follow-up and the low risk of dementia does not weaken but rather reinforces the conclusions of the dementia project.
Before randomisation, the SystEur patients were stratified for centre, sex and previous cardiovascular complications. The patients of the two treatment groups had similar baseline characteristics. 3, 4 Thus, there is no ground for the speculation that the mechanism explaining the low risk of dementia in the SystEur patients randomised to placebo, would have had an even more profound effect on the active-treatment group. Furthermore, although in the Syst-Eur trial the risk of dementia was lower than in some other prospective studies, 6, 7 this was not the case in comparison with the community-based Rotterdam study, if one properly accounts for risk factors such as age and smoking. 8, 9 Indeed, the incidence of dementia in the Rotterdam study was 9.9 cases per 1000 patient-years. As in the Syst-Eur trial, the diagnosis relied on the Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R) criteria. 10 The participants in the Rotterdam study, compared with the SystEur patients, had the same mean age (69.3 vs 69.9 years), but included three times more smokers (20.7% vs 7.3%).
Dr Clarke also dismissed the supportive evidence in that in the Syst-Eur report the relationships between the changes in blood pressure and those in the test scores of the Mini Mental State Examination (MMSE) 11 were significantly different between the two treatment groups. The nimodipine studies 12 to which Dr Clarke refers were not designed to test whether calcium-channel blockade would prevent dementia. Indeed, the patients randomised in these double-blind placebo-controlled trials 12 were already demented. These studies 12 failed to show an improvement of cognitive function as evaluated by the Alzheimer's Disease Assessment Scale 13 or the Clinical Global Impressions-Global Improvement scale over a 26-week period, but they did show that the MMSE 11 scores decreased less in the patients on nimodipine than in those randomised to placebo. The observation that antihypertensive treatment with a thiazide did protect against cognitive impairment in the Systolic Hypertension in the Elderly Program (SHEP) 14 argues against the hypothesis that degenerative dementias would be prevented by just lowering blood pressure. Alternatively, the negative SHEP findings may also be attributed to the selection of healthier patients than in the Syst-Eur trial and to the consequently lower incidence of dementia (approximately five cases per 1000 patient-years).
We agree with Clarke's suggestion that the Syst-Eur findings must be confirmed. 3 Future intervention studies must explore the possibility that long-acting dihydropyridines, in comparison with thiazide diuretics, many confer specific neuroprotection. 15, 16 Dihydropyridines readily cross the blood-brain barrier, 17 have specific binding sites in those areas of the central nervous system which are most severely affected by Alzheimer's disease, 17 and reduce the turnover of monoamine neurotransmitters, 18 of which many are deficient in degenerative dementias 16 . The intracellular calcium concentration increases with age and in the presence of beta-amyloid, may sensitise neurons to proinflammatory substances and pro-oxidants. 16 Whether or not dihydropyridines, over and above their blood pressure lowering effect, may inhibit or reverse this process remains to be proven. 
